HK1214504A1 - 用於治療貧血的方法 - Google Patents
用於治療貧血的方法 Download PDFInfo
- Publication number
- HK1214504A1 HK1214504A1 HK16102359.3A HK16102359A HK1214504A1 HK 1214504 A1 HK1214504 A1 HK 1214504A1 HK 16102359 A HK16102359 A HK 16102359A HK 1214504 A1 HK1214504 A1 HK 1214504A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- treating anemia
- treatment
- anemia
- gdfl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261718128P | 2012-10-24 | 2012-10-24 | |
| US61/718,128 | 2012-10-24 | ||
| PCT/US2013/066353 WO2014066487A2 (en) | 2012-10-24 | 2013-10-23 | Methods for treating anemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1214504A1 true HK1214504A1 (zh) | 2016-07-29 |
Family
ID=50545463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16102359.3A HK1214504A1 (zh) | 2012-10-24 | 2013-10-23 | 用於治療貧血的方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20150266950A1 (zh) |
| EP (2) | EP2911682A4 (zh) |
| JP (3) | JP6401172B2 (zh) |
| CN (3) | CN112957462A (zh) |
| AU (4) | AU2013334660B2 (zh) |
| CA (1) | CA2889286A1 (zh) |
| HK (1) | HK1214504A1 (zh) |
| NZ (1) | NZ747350A (zh) |
| WO (1) | WO2014066487A2 (zh) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2839549T3 (es) | 2005-11-23 | 2021-07-05 | Acceleron Pharma Inc | Antagonistas de activina-ActRIIa de utilización en la estimulación del crecimiento óseo |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| MX2009008222A (es) | 2007-02-01 | 2009-10-12 | Acceleron Pharma Inc | Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama. |
| TW201803890A (zh) | 2007-02-02 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| BRPI0807506B1 (pt) | 2007-02-09 | 2022-02-15 | Acceleron Pharma, Inc | Uso de uma proteína de fusão actriia-fc para a fabricação de um medicamento para tratar ou previnir mieloma múltiplo |
| EP2207562B1 (en) | 2007-09-18 | 2017-05-31 | Acceleron Pharma, Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| PL3494986T3 (pl) | 2008-08-14 | 2020-11-16 | Acceleron Pharma Inc. | Pułapki GDF |
| JP5912078B2 (ja) | 2009-06-08 | 2016-04-27 | アクセルロン ファーマ, インコーポレイテッド | 熱発生性脂肪細胞を増加させるための方法 |
| JP2012529294A (ja) | 2009-06-12 | 2012-11-22 | アクセルロン ファーマ, インコーポレイテッド | 切断型ActRIIB−Fc融合タンパク質 |
| CA2781152A1 (en) | 2009-11-17 | 2011-05-26 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| EP2638065A4 (en) | 2010-11-08 | 2014-04-09 | Acceleron Pharma Inc | ACTRIIA-BINDING SUBSTANCES AND ITS USES |
| HK1214504A1 (zh) * | 2012-10-24 | 2016-07-29 | 细胞基因公司 | 用於治療貧血的方法 |
| NZ707477A (en) | 2012-11-02 | 2019-09-27 | Celgene Corp | Activin-actrii antagonists and uses for treating bone and other disorders |
| US20160046690A1 (en) * | 2014-03-21 | 2016-02-18 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| TN2016000553A1 (en) | 2014-06-13 | 2018-04-04 | Acceleron Pharma Inc | Methods and compositions for treating ulcers |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| EP4233889A3 (en) | 2014-12-03 | 2023-10-11 | Celgene Corporation | Activin-actrii antagonists and uses for treating myelodysplastic syndrome |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| EP3256148A1 (en) * | 2015-02-12 | 2017-12-20 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
| MY189601A (en) * | 2015-05-13 | 2022-02-18 | Celgene Corp | Treatment of beta-thalassemia using actrii ligand traps |
| US10548976B2 (en) | 2015-05-20 | 2020-02-04 | Celgene Corporation | In vitro cell culture methods for beta-thalassemia using activin type II receptor ligand traps |
| US11123430B2 (en) | 2015-11-04 | 2021-09-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| LT3496739T (lt) | 2016-07-15 | 2021-05-25 | Acceleron Pharma Inc. | Kompozicijos ir būdai, skirti plaučių hipertenzijai gydyti |
| SI3490582T1 (sl) | 2016-07-27 | 2024-09-30 | Acceleron Pharma Inc. | Sestavki za uporabo proti zdravljenju mielofibroze |
| US11013785B2 (en) | 2016-11-10 | 2021-05-25 | Keros Therapeutics, Inc. | Activin receptor type IIA variants and methods of use thereof |
| CN107011430B (zh) * | 2017-04-07 | 2020-09-01 | 哈尔滨医科大学 | 一种具有生物学活性的截短的生长分化因子11及其制备方法 |
| EP4428147A3 (en) | 2017-11-09 | 2024-10-30 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| AU2019206634B2 (en) | 2018-01-12 | 2024-06-27 | Keros Therapeutics, Inc. | Activin receptor type IIB variants and methods of use thereof |
| CA3098679A1 (en) * | 2018-05-09 | 2019-11-14 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| WO2020257587A1 (en) * | 2019-06-19 | 2020-12-24 | Cornell University | Methods of promoting erythropoiesis and overcoming erythropoitein resistance in patients |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| EP4121078A4 (en) | 2020-03-20 | 2024-08-14 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| CN113801880B (zh) * | 2021-07-27 | 2024-11-01 | 浙江大学 | 一种通过靶向敲除基因建立的早衰细胞模型及其sgRNA、构建方法和应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| EP1574577A3 (en) * | 1994-07-08 | 2006-06-14 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-11 |
| US7795202B2 (en) | 1997-08-04 | 2010-09-14 | Neurorepair, Inc. | Methods for treating a neurological disorder by peripheral administration of a transforming growth factor alpha (TGF-a) |
| EP1100887A4 (en) * | 1998-07-28 | 2003-01-15 | Univ Johns Hopkins Med | Growth differentiation factor 11 |
| TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| PL374966A1 (en) | 2002-02-21 | 2005-11-14 | Wyeth | Follistatin domain containing proteins |
| AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| EP3489257A1 (en) | 2004-07-23 | 2019-05-29 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
| MX2007011591A (es) * | 2005-03-30 | 2007-12-10 | Wyeth Corp | Metodo para estimular el crecimiento de cabello administrando bmps. |
| WO2007006025A2 (en) * | 2005-07-01 | 2007-01-11 | Acceleron Pharma Inc. | Lefty, lefty derivatives and uses therof |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| ME02335B (me) | 2006-12-18 | 2013-04-30 | Acceleron Pharma Inc | Activin-actrii antagonisti i upotreba za liječenje anemije |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| TW201803890A (zh) | 2007-02-02 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| TW201718635A (zh) | 2007-03-06 | 2017-06-01 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| US8236751B2 (en) | 2007-03-07 | 2012-08-07 | The Johns Hopkins University | Methods of increasing muscle mass using follistatin-like related gene (FLRG) |
| EP2207562B1 (en) | 2007-09-18 | 2017-05-31 | Acceleron Pharma, Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| EP2318028B1 (en) * | 2008-06-26 | 2020-02-19 | Acceleron Pharma Inc. | Antagonists of soluble activin-actriia and uses for increasing red blood cell levels |
| PL3494986T3 (pl) * | 2008-08-14 | 2020-11-16 | Acceleron Pharma Inc. | Pułapki GDF |
| US8216997B2 (en) * | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| KR20200124322A (ko) * | 2009-08-13 | 2020-11-02 | 악셀레론 파마 인코포레이티드 | 적혈구 수준을 증가시키기 위한 gdf 트랩과 에리트로포이에틴 수용체 활성인자의 병용 |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| WO2012027065A2 (en) * | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
| EP2638065A4 (en) * | 2010-11-08 | 2014-04-09 | Acceleron Pharma Inc | ACTRIIA-BINDING SUBSTANCES AND ITS USES |
| HK1214504A1 (zh) * | 2012-10-24 | 2016-07-29 | 细胞基因公司 | 用於治療貧血的方法 |
-
2013
- 2013-10-23 HK HK16102359.3A patent/HK1214504A1/zh unknown
- 2013-10-23 EP EP13849960.3A patent/EP2911682A4/en not_active Withdrawn
- 2013-10-23 US US14/438,127 patent/US20150266950A1/en not_active Abandoned
- 2013-10-23 NZ NZ747350A patent/NZ747350A/en unknown
- 2013-10-23 CN CN202011542063.1A patent/CN112957462A/zh active Pending
- 2013-10-23 WO PCT/US2013/066353 patent/WO2014066487A2/en not_active Ceased
- 2013-10-23 JP JP2015539751A patent/JP6401172B2/ja active Active
- 2013-10-23 CA CA2889286A patent/CA2889286A1/en not_active Abandoned
- 2013-10-23 CN CN201380067832.9A patent/CN104981250A/zh active Pending
- 2013-10-23 AU AU2013334660A patent/AU2013334660B2/en active Active
- 2013-10-23 CN CN202011541918.9A patent/CN112933223A/zh active Pending
- 2013-10-23 EP EP19151143.5A patent/EP3527219A1/en not_active Withdrawn
-
2018
- 2018-07-12 JP JP2018131952A patent/JP2018184430A/ja active Pending
- 2018-11-02 AU AU2018256635A patent/AU2018256635A1/en not_active Abandoned
-
2020
- 2020-05-15 AU AU2020203198A patent/AU2020203198B2/en active Active
- 2020-06-24 JP JP2020108654A patent/JP2020183390A/ja not_active Withdrawn
-
2022
- 2022-03-21 AU AU2022201923A patent/AU2022201923A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020183390A (ja) | 2020-11-12 |
| AU2013334660A1 (en) | 2015-05-14 |
| AU2018256635A1 (en) | 2018-11-22 |
| AU2020203198A1 (en) | 2020-06-11 |
| JP6401172B2 (ja) | 2018-10-10 |
| AU2013334660B2 (en) | 2018-08-09 |
| CN112933223A (zh) | 2021-06-11 |
| WO2014066487A3 (en) | 2014-06-19 |
| JP2018184430A (ja) | 2018-11-22 |
| EP2911682A2 (en) | 2015-09-02 |
| JP2016503398A (ja) | 2016-02-04 |
| AU2022201923A1 (en) | 2022-04-14 |
| CA2889286A1 (en) | 2014-05-01 |
| AU2020203198B2 (en) | 2021-12-23 |
| US20150266950A1 (en) | 2015-09-24 |
| WO2014066487A2 (en) | 2014-05-01 |
| EP2911682A4 (en) | 2016-03-23 |
| CN112957462A (zh) | 2021-06-15 |
| NZ747350A (en) | 2020-07-31 |
| EP3527219A1 (en) | 2019-08-21 |
| CN104981250A (zh) | 2015-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1214504A1 (zh) | 用於治療貧血的方法 | |
| HK1202800A1 (zh) | 成纖維細胞生長因數21蛋白質的治療用途 | |
| AU2018260809A1 (en) | Compounds and uses thereof for the modulation of hemoglobin | |
| AU2018256591A1 (en) | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections | |
| MY191087A (en) | Compounds and uses thereof for the modulation of hemoglobin | |
| WO2016037157A3 (en) | Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies | |
| MY169159A (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
| MX2015011509A (es) | Compuestos y usos de estos para la modulacion de la hemoglobina. | |
| PH12012501830A1 (en) | Bispecific, bivalent anti-vegf/anti-ang-2 antibodies | |
| MX2013004061A (es) | Analogos de ciclosporina. | |
| EP4414376A3 (en) | Novel depsipeptide and uses thereof | |
| WO2015171965A3 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
| PH12015500724A1 (en) | 1, 2, 4-triazine derivatives for the treatment of viral infections | |
| MX2024008826A (es) | Composicion para la estimulacion ovarica controlada. | |
| PH12013502529A1 (en) | Freeze-dried formulations of fgf-18 | |
| WO2015058664A8 (zh) | 淫羊藿苷元在制备预防或治疗血细胞减少药物中的用途 | |
| WO2013181339A3 (en) | Cyclosporin a analogs | |
| WO2011156811A3 (en) | Compounds for treatment of bovine mastitis | |
| WO2016011049A3 (en) | Compositions and methods for disease treatment using nanoparticle delivered compounds | |
| WO2015001163A3 (es) | Nanopartículas lipídicas para la cicatrización de heridas | |
| MX366829B (es) | Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas. | |
| WO2015048188A3 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
| WO2013038200A3 (en) | Neurodevelopmental disorders | |
| WO2013055825A3 (en) | Guanidinyl-substituted polyamides useful for treating human papilloma virus | |
| WO2012112438A3 (en) | Anti-microbial agents and compositions and methods of production and use thereof |